在复发性BALB/c小鼠结核病模型中，用氨甲环酸MBX-4888A替代利奈唑胺用于Nix-TB方案时的杀菌活性。
Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis.
作者信息
Peroutka-Bigus Nathan, Sherman Michael S, Kaya Firat, Waidyarachchi Samanthi L, Liu Jiuyu, Rushefsky Joel, Butler Michelle M, Bowlin Terry, Meibohm Bernd, Gonzalez-Juarrero Mercedes, Lenaerts Anne J, Zimmerman Matthew, Lee Richard E, Robertson Gregory T
机构信息
Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
出版信息
bioRxiv. 2025 Aug 6:2025.08.04.668403. doi: 10.1101/2025.08.04.668403.
Spectinamides have garnered interest as experimental tuberculosis therapeutics owing to their safety profile and efficacy as partner agents when used in conjunction with established regimens in mice. The Nix-TB regimen of bedaquiline, pretomanid, and linezolid represents a short, effective regimen recommended for treatment of pre-extensively drug-resistant tuberculosis. However, linezolid administration is associated with severe adverse events which limits its use. Here we present preclinical data that spectinamide MBX-4888A can replace linezolid in Nix-TB.
由于其安全性以及在小鼠中与既定方案联合使用时作为辅助药物的有效性，氨甲酰基环醇类化合物作为实验性结核病治疗药物引起了人们的关注。贝达喹啉、普瑞玛尼和利奈唑胺的Nix-TB方案是一种推荐用于治疗广泛耐药前结核病的短程有效方案。然而，使用利奈唑胺会出现严重不良事件，这限制了它的应用。在此，我们展示了临床前数据，表明氨甲酰基环醇类化合物MBX-4888A可在Nix-TB方案中替代利奈唑胺。
Zotero 插件